Pubblicazioni primo autore Valentina Guarneri

25 08, 2021

Valentina Guarnieri et. al., PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.

Diatech Pharmacogenetics2021-01-05T12:31:00+01:00

15 09, 2015

Valentina Guarneri et al., Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. The Oncologist

Diatech Pharmacogenetics2017-08-08T09:48:41+02:00

14 04, 2014

Valentina Guarneri et al., Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer. Journal of Clinical Oncology

Diatech Pharmacogenetics2017-08-09T08:52:27+02:00